HUE032252T2 - 2'-fluorszubsztituált karba-nukleozid analógok antivirális kezelésre - Google Patents

2'-fluorszubsztituált karba-nukleozid analógok antivirális kezelésre Download PDF

Info

Publication number
HUE032252T2
HUE032252T2 HUE10763083A HUE10763083A HUE032252T2 HU E032252 T2 HUE032252 T2 HU E032252T2 HU E10763083 A HUE10763083 A HU E10763083A HU E10763083 A HUE10763083 A HU E10763083A HU E032252 T2 HUE032252 T2 HU E032252T2
Authority
HU
Hungary
Prior art keywords
another aspect
compound
alkyl
methyl
ora
Prior art date
Application number
HUE10763083A
Other languages
English (en)
Inventor
Aesop Cho
Choung U Kim
Samuel E Metobo
Adrian S Ray
Jie Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HUE032252T2 publication Critical patent/HUE032252T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C7/00—Multicolour photographic processes or agents therefor; Regeneration of such processing agents; Photosensitive materials for multicolour processes
    • G03C7/30—Colour processes using colour-coupling substances; Materials therefor; Preparing or processing such materials
    • G03C7/32—Colour coupling substances
    • G03C7/36—Couplers containing compounds with active methylene groups
    • G03C7/38—Couplers containing compounds with active methylene groups in rings
    • G03C7/381—Heterocyclic compounds
    • G03C7/382—Heterocyclic compounds with two heterocyclic rings
    • G03C7/3825—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms
    • G03C7/3835—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms four nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

  1. : SZABADALMA K AZZ Υ!Α>ΒΑΌΚ I. Kéfska:1 Hierin·; vagyPB·;
    vagy aggaR |ÿogLfiâ«ï®s»î:Ül8g altSgakfesRs A-a. akgí: R: AY-CAMbl. AÇCyAA^SmLosABIaAïI, ΑΖ:·Ο0νν;Α··.>:;ννΖΑ· äML {CrC0;kk.eO;, %€%* ZZBaubv/Lïuàk alkynlL (OrCygROgp,:{C;OZ> AaD;ya;:uuaii alb*·:!;, vagy «ïïKL ; ·Βγ3!κ·Ι: &amp;;ί F; rmrukgysk R;Z RL vagy B: ÁlggOksSR E; OR:: NZR:T, % CN. NO:. SfORRA kifeg&amp;y.AV |CS ASIksíAöeildíARsL {CágCLEKKks^BmálíiS&amp;iL Air A VkksttA As«I» : Brr LVaAksnii. (L'i>CE: HaVrRrtOI·: albail vagy aniVVCDalkil: vagy RA vagy RZ: RAOJ iÄ.gg>!ÖÄ -««ssk *£*&amp;> ->CS€:€BLL vagy La '$ .gyfe! $#ö&amp;t«TOkM -egyi# va&amp;öálc··' v&amp;»s aradyekbea kapsalöRaatg ÍRstRB MOa alkögyÁ; R'-' HZ ORL DsRLA 1% m, WLL, S(OLRZ TAVÁRA TVO}OR:! -: í AB>V?:VA ,· U'OARi! SBAR'5 -Srr.R Z-NOgoRV -MOhORA ΑΓαΝΚ’Β A b*k>gva; iZVVkkkA DA VOkaVxnkValksk ΚΥΤΜ^νη-χΑνΑ· aikk. íC?·--ZJWmi. AAyk B'xvoaaasvak dVsM (WZ ;a;ksaA (C- ·ΖννχνΜδ··ν<δ1Ι .AkusA vagy adRSZALOlkU:; asmdágyA ë íSpMisaúi CL I, vagy A /sainé^yft: R- iagpLaaRl H, |CdÇÿteM> (CaASMkDëk {Ç^-C'ylSIkmili ádLCrRdZSAl %€.e Cvjkaaboylkklslkik ΤΑΜΠΑ' ·α··Ο;0ΗΑ <p|ffi*!Es( -OL«O^RäB A<0}R:'; S;Oy.R:! S:d?}COR;V ••OOï;(Ok;î>. vagy ·ΑΟ:ΜΗ/V;:: R' JR --ÊÎ-Op5··:, Ayr spAZ -ZY-v);NRî;R!Z ••CVT.>}SHîZ AALëirZ - VOyA : V(0=fORV. AíZAaORV, -SOARSâlSA vagy
    íVvíKiagyik V vagy A' .> OgpRasaRk (Z S. BR, iSR/gRy NiOAr VALA/kr vagy VN Kr W! kg WA ras agyán v.vsraA vr'c, · YXCiRAdA' ·: vagy W':" vagy W“ egyiks agyiig R -a; vagy >0 ·a i Y’·· V W- vagy SY aágsika kàpkaZkg vagy % s i. W? •rë Vegyik. ikgp;k-rak. g:képiát ia C'Agtí^ftja:
    képi et -a aksl: xMxCgyR V füageslcixl kopp O, ClC. NR. ''NkÖ)Pk EPRIÄ· MR S(O). vagy $sO>g r-xndagyR V ' kíggcíi'a-al { >.. R. vágy ÇR;. M2 0. 1 vagy 2; smsdvgyik k ' IbgpíRsml Fv vagy a képivP
    ahol: MibdvgyiiMR., MI% éMlá iagggsfepälÖ vagy g; M:i,2e (·, U. MC 5, b, 7:, I, CIC P vagy 12. mMifegyik P· JgglÄpi.R I, Cl Br.t OH. R, MuYlR. RRYRBUCrYRNíR};, -NpR -IMEh. RE, URRk -SRRR. URRPR), PCMMEkPCRPM, RPHl*)ORf RX:vRRRv{PR -SCRRS:Ä MCRR^lRRCpM^KMí&amp;M, PlEppPp, RiR}RR'RMC Rpy Y1N(RU ROUIR -CN. ->R NQ;·. -OR, vagy lR \agy ha egvüís vaxsR ν<·ν<·. ksstd S?'ggyappop a vgégapggpg gp íváaaianvv; karlvx :kkis;v: gyünk alkxs. ipkxlégysk R ibgpRsxüi Η, iílty Obi (*.'rCs; ssuMstitsíák afkü. (CRlPlxbl prCxJ «xvbpRuáls aCetal. sORR Obnl pyCR \/al':-.«xiud: alklnll, 0,-,-0.:.. : aki, CpCR pbbsábsph «ni, CM CRkeiäxöcjkli CRC;» aaubsBíkaál hvseíoUklb, asRaPl vagy saubsaallaáliánialkil; W:s Xr vagy W'l Ív R, -CURRY Rxps:)Wk --R.RRY vagy MCRWy és Xm kaiM-okUs vagy hvsVsOí ikkn. aixxi XM iggptlggöl SpMsgklRRa vás 0-' R.v csapokkal: rMvdcgyxk X' va y y R Ogp-ü«xx;l CRU Vagy kg îvnKlsgvik !C Rlpvn, NlRU- RRRîRR NR:iHR>:R:;:. R, NU l?ûy CEO, CM · CIÏONRM. -CR-MNÜRR -ClOMÖlU}. -011(010%, --OO-CONRRÜ, XR-RNkRU. P(ppE:% R k -Op-dkR RY-Oplkaxil b-VC-pîbad. ; R: ·<.ν }k« r ;x· a ill I a !ki I. yjwbsgksaa sxOx-R-xsáis aál. gpUgpáysáá sspbsgpígáR by Ms oapl -- Cf - CRC ;-Cl kék ü, ~ SP/RC ;-Cpyl ksi, sxsiiRl -·(,,.· alk il DR*! Vagy SRU adak-gvA K': Vágy R:í? tliggaSgag! II. Idôgés, NK’Ri ', N{R;}OR;;. NR:’:NF!>F'\ :¾ NO. NO;.. CB.O. COy -CHs- NRî:}, <:||-ΝΒΝΕ5% -Otl“:NI0Ei:% -€lf DE.J%, -C;-0}NR’;R. -C. d:SjNR:sR; :v R 's OR ' V«gy SR''y mmaNgyN R:: y&amp;gv Ru RiggONÄ il ίΟνΑΑΙΝΝ!, iCR'Ç's)«Ik«mS (CO-Vîa&amp;ûnL (Qr· CfjksrbocMHnikű. ypcvaasösaa aadvvdavákM|s ggyRíRSIÓag NRgsoAÂORyrôsnli R.OkdNyàkkiNk, 0(0}kCrk ONkH 'Agy 5iHKC:.-\N);SkF:. vagy R.i! O F.':> agyik; véva ndogdi.aO. aasdybax remised kajWSÖióáik«. 3-1 tagg keRyociki&amp;aox gyúrd ORgg Not 8 togatRikhoo gy%g kâtmdy xOyakg'ag ypggxâàS-sïa:: ál fehd: csgaeNg a xgvgRgNivd: -O·. ··$>· vagy -NRA : ahol 'nhidagya· F\ F.; Rk Rk Rk R!' vagy K. ' -xiNdegy-xk {<R-C's1alkiNás fCyCogfkkgffjó (Ckr kR}alO.«.3jg a ágy anitkVíkAdkitjg iRggySglyly op< kaNiNay axubokoNvg Vág egyyd vagy tőRRN s kF'· :M ka go!··. koad: hak; hkRoxi, CN. Ns, N-Rk; vagy OKk : <N. ahoi -rurak gyA {C rC;;::kki] sem RrmkíáiN saäisNöma MAR;agy vagy ókh opekaNjlOïakikayOlhyO &amp; kovafeadvak -fik,. -Sk vagy «MRO ÍNAvv. hagy kápks 1 aaoimi vagyak?* naa?·* rapvvogAtva a AWokaxk kgylNgk: sgyNy ágaisam, aíndvhaa R fi:
    vagy
    g, A:.·, \, fgSgypöíg agg-ka; vagvúO:. a-ndyO kap kl k u-pccacnO;
    képlet g :tK;i ípinskgy;!; Ÿ <A Y'' 0; .%* (. R:" vagy 0 0 0* Cli vagy amuk gy6gyyyoAx«A?tg β|ί<0<0|00 gôjg vagy gyaí-ev 1, A:·? I., v:sgy I Kkvygvvu v'vrsRi svgyükl. ahY A' lélefét!, Nk:!;k.!<V0(0!í;K10* \ MR^HReR'1 OR;s vagy yR:;.
  2. 4, As M gkvupORKAAarReipke vegyük;. .;shoí R' H.éslegAt SIR! vagy NR; R: :.
  3. 5. As i -4 jg:í:'iyp;;ns->k bâtadyPr sásílali yygpAM, sSal R* It ORl CN. mdig íí-eni; vagy VA«.:.! S. Aí 1-:¾ ig0Hi>os:U0 blrneiyiky-evkn;: vagyüp·. ;η·;>: H” H. I. Ak 1-5, igympvaek bamvayAc yyyrmk vygyukt ah«: Rt CSi A. Ai ]··'? 0y:Hiy>i:í;>kA;k:':eivikc aygrínu vegyük*, ;Ad R ’ 0R;< R; Λ/ s A. igéaypoiuok teaeiyA» Síiéin:« vegyüku y.radyvi .káple III egvryggmil
    képl et ; ,ïî: alp! R: SAP] va gy #í:i A k vagy isissé gyógy spiéasvRISg Sí Rspákise alga vágy : Maíáív. JŐ, Ae lAg:]gss5sRaSög: b0S5s]yAs sgstSS vsgyület &amp;hö! R Yi vagy
    II. Λ;·: MR. iggöypssslefc h*ns;dy:kv ageist vggySki aboi R A.s 1-1 L igénjpftnîiïk xícdni; vssyük'·. a.hni R' €:%;
    13:·. Λ:·? :L |gëiiÿ|S?>sk szénán scgyiïkt s-sdyncx 1<φκ··<·:
    v?£gy d.lbg::tdMîô $?:>d vágy dssísrs. H. À Mglsif vvgvük·::
    vsgy
    vsgy siíöi&amp;k gÿôgÿsÂSïkSÂSÎslaf: slfepsÄkk sôj&amp; vsgv éssíseís, |5- Vcgvxiki Singly ha-BiO'. kgglgî I sgsikl|i vnsyiije) glMIkfàgâig, Sïndy ki ν;κ· vlikÄy* ;s ki>vcikftk>k;xH siló ssofkktk&amp;l «ΏδΙ
    VóS.y Æ'ïîv.ik vagy IS. Gw^ïeKssteïî **«# «rtalma^ïa i- ven'îvi '^>x9« *&amp;&amp;%%* ¾ 'S.'' ' <\i V' v X \\\ ν' V' ' ν'.***'*''*5 V 'IvÍví^V í' : ? K>. UKtV :U g>%> «***<* *«"Ρ««*'· KW) V lovftbt* t«**»*** fe'â*^bb k?y SAVÉ«: r**>* wa «Mi; Ki vsa :mr*z 3 It^^kbói álló cs<,>onbki infcrlwanok, ntevróe ^ analóg*», HCV NS:l p-xkefe NS5» hxbibik%>L Ä-gkste:«^* l mMmvk, ssp|y#®k nttvjfawii <kkartK**fe w!»%or-*ék. ron^s«?»»«^ ttttfaeer ap^!«Ä*Ä:^Ä:;Ä r i^vHkuvv^'s »s'. V>'H V ' '»* «»· iv i' w\ vk'w^v i'*«' ' * ' x \v s wm »»kKwul iAiub^kTJK HCV NS5A inhibkotuk, 1 LR-·'? ogwuÄ cMoMba «eMntuiok. HCV t» .» k'viV <- V'UXk'^v * V vkww VW' M,· Az M4. (ge«^H>«tok igyik« sxmßti v«gväfes feHmznâiàsrii >/:nkon;
  4. 19. Αχ i..|4. igé»>pö«*xk egyife saKíoti vegyiil« M*as*a*ia.w3 tlavtvirniG« vu® infekctó ke:?e)éáéfeej5.
  5. 29. Λ Hb jgeiiypoïii víenati v;?|;y'äkn. <skoi i! Xii-xks Assy'kjo ?Ie;x^iiP* k x»^fe ,.s>k..v.....s·. 21. Ä 19. va^ylO. sgasypom «termi vegyid. tfoi &amp; k» «Ί*" " '** v V4V; ’ íRütóasü ok<>
  6. 22. KvAw-ik neyrurtd*' ^ xwy t*^™*** a ^ v'XWv V k\ V iit ννΆ v'i't a- ΐν>ν.Φ'Χι V IäI* " \**ν4<' Í V (,'v.vK': ·.. v|l Λ . . ' . .. V v^K-ivi ' \.'A. ;->'vä-'9 2\ v'Op".tKí «kOî'k 'ski's'.!'.' 'ài'> '!"'ik>í “ X "λ' {'*"' inhibitc-îv>k; kiSSâ ïiîhâbstorok. skkgkkA.£usài: i im»hitor»>k, nsäjxi^-k, ΐ>.ιΛΐί>.χ...»ν v-ws-,.·. vs >X»\\AS.4v K' Îv'ii|vSv <·> ' idvvi 'iSV1'.·'!« U V. V îv A i k '! tK Î'X 'â! b jVviN ' MCV NS5&amp; pohamL· irfMl mm «ÄÄ MtMtmzl HCV NS5B -.*<*«****· **»- nâtetutd Âfest^k mm mmJÆmwe^, *#· *g*Ä% ääb &amp;*^· .^Τϊξΐ^ίςΐίκΙ^άΐ^κίίκ^ïï^siwisïrÎiili: <ΐΗ··:ϊϊ^!&amp;..gÿxSiíji^'isgláiBéíréj!: x^P svzes- kv-vK-s..*
  7. 23. ..M i ':i9. i0n$$mhk·Äf%j^j&amp;ß f^'öigr-feö^^5*4^' ι..χχ·.> rhvsviriàùi: vímv iiäfefesiiä k*>:<·iéséí« sxasgsL 29. A 23 jgé«>pí»ií vœtinti fclh«sK«áíás. ahol s ftexr«riáe<.' vin» xabk-wi an* i *xrm Amm. fi A 23. vagy 24. >g«syp«sS g«»ä feihaxsAáls·;, 3ÍKsi ;i vsriA míbíccíoí Mepíibs c saniíi Sks.í-'í' .Tm-itánüü-oka»»«. îè. .Aí 1--IS ig-'iïsypv'îpok bára-dyik« triais vegyülç-t ..... Alkbâiyïi'Äb: x?|a§:;:lsSskexi.'|tegs9i| Wif·.k': v^i:;; Si'tck'K> :a*I:?sx sr:5!Ï''': :'"k kvsxalèXvriî vsgv pravsincs;yàra sköJgSl;
HUE10763083A 2009-09-21 2010-09-20 2'-fluorszubsztituált karba-nukleozid analógok antivirális kezelésre HUE032252T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24429709P 2009-09-21 2009-09-21

Publications (1)

Publication Number Publication Date
HUE032252T2 true HUE032252T2 (hu) 2017-09-28

Family

ID=43031517

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10763083A HUE032252T2 (hu) 2009-09-21 2010-09-20 2'-fluorszubsztituált karba-nukleozid analógok antivirális kezelésre

Country Status (32)

Country Link
EP (2) EP2480552B1 (hu)
JP (3) JP5795766B2 (hu)
KR (2) KR101818779B1 (hu)
CN (1) CN102596958A (hu)
AP (1) AP2012006189A0 (hu)
AU (4) AU2010295373B2 (hu)
BR (3) BR122021021135B1 (hu)
CA (1) CA2773772C (hu)
CL (1) CL2012000707A1 (hu)
CR (2) CR20190103A (hu)
CY (1) CY1118605T1 (hu)
DK (1) DK2480552T3 (hu)
EA (1) EA201200525A1 (hu)
EC (1) ECSP12011817A (hu)
ES (2) ES2614651T3 (hu)
HR (1) HRP20170197T1 (hu)
HU (1) HUE032252T2 (hu)
IL (2) IL218599A (hu)
LT (1) LT2480552T (hu)
ME (1) ME02656B (hu)
MX (1) MX352646B (hu)
NZ (1) NZ599402A (hu)
PE (3) PE20120995A1 (hu)
PL (1) PL2480552T3 (hu)
PT (1) PT2480552T (hu)
RS (1) RS55699B1 (hu)
SG (1) SG179194A1 (hu)
SI (1) SI2480552T1 (hu)
SM (1) SMT201700091B (hu)
UA (1) UA110466C2 (hu)
WO (1) WO2011035231A1 (hu)
ZA (1) ZA201202175B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2937350T (lt) 2008-04-23 2018-04-10 Gilead Sciences, Inc. 1'-pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
US7973013B2 (en) * 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
MX352646B (es) * 2009-09-21 2017-12-04 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral.
PT2752422T (pt) * 2010-03-31 2017-11-07 Gilead Pharmasset Llc Síntese estereosseletiva de princípios ativos contendo fósforo
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
CA2804375C (en) 2010-07-19 2018-08-21 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
KR101821680B1 (ko) 2010-07-22 2018-01-24 길리애드 사이언시즈, 인코포레이티드 파라믹소비리대 바이러스 감염을 치료하기 위한 방법 및 화합물
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
SG188223A1 (en) * 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
EA201691695A1 (ru) 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EA026667B9 (ru) 2011-09-16 2017-07-31 Джилид Фармассет Ллс Фармацевтическая композиция для лечения вируса гепатита с
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SI2834258T1 (sl) 2012-03-13 2017-04-26 Gilead Sciences, Inc. 2'-substituirani karba-nukleozidni analogi za protivirusno zdravljenje
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US9242988B2 (en) 2012-10-17 2016-01-26 Merck Sharp & Dohme Corp. 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014059902A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
EP2919792B1 (en) 2012-11-19 2020-05-20 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3010512B1 (en) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
WO2016160646A1 (en) 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
CN104945437B (zh) * 2015-05-19 2017-03-01 广州诺威生物技术有限公司 一种嘧啶类新化合物
HRP20220740T1 (hr) 2015-09-16 2022-11-11 Gilead Sciences, Inc. Postupci za liječenje virusnih infekcija arenaviridae
CN109071467B (zh) 2016-03-09 2023-04-04 艾丽奥斯生物制药有限公司 无环抗病毒药
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
CN109476668B (zh) * 2016-07-14 2022-03-22 豪夫迈·罗氏有限公司 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物
AU2017311566A1 (en) * 2016-08-12 2019-02-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
BR122022008466B1 (pt) 2017-12-07 2023-12-05 Emory University Uso de um composto
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
US20230167117A1 (en) * 2019-02-07 2023-06-01 Beigene, Ltd. Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
JP2022531899A (ja) 2019-05-09 2022-07-12 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CN114641299A (zh) 2020-01-27 2022-06-17 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
AU2021281351A1 (en) 2020-05-29 2023-01-19 Gilead Sciences, Inc. Remdesivir treatment methods
BR112022026321A2 (pt) 2020-06-24 2023-01-17 Gilead Sciences Inc Análogos de 1'-ciano nucleosídeo e usos dos mesmos
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
WO2022219636A1 (en) * 2021-04-14 2022-10-20 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds, and uses thereof
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
JP2024518530A (ja) * 2021-05-14 2024-05-01 ビーエム ファーマ コンサルティング ピーティーワイ リミテッド ウイルス感染の予防及び治療のための二環式複素環化合物
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CZ20022825A3 (cs) 2000-02-18 2003-05-14 Shire Biochem Inc. Analoga nukleosidů pro použití při léčení nebo prevenci infekcí způsobených flavivirem
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
US20040006002A1 (en) 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
HUE033832T2 (hu) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-metil-nukleozidok, interferonnal és Flaviviridae mutációval kombinációban
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7842672B2 (en) * 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2673649A1 (en) 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CA2674589A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US8188272B2 (en) 2007-03-21 2012-05-29 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
LT2937350T (lt) * 2008-04-23 2018-04-10 Gilead Sciences, Inc. 1'-pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
MX352646B (es) * 2009-09-21 2017-12-04 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral.

Also Published As

Publication number Publication date
AU2016262676B2 (en) 2018-03-29
EP3150608A1 (en) 2017-04-05
KR20120102605A (ko) 2012-09-18
BR122021021135B1 (pt) 2022-08-30
BR112012006261B1 (pt) 2021-12-21
EP2480552B1 (en) 2016-11-09
EP2480552A1 (en) 2012-08-01
BR122021012877B1 (pt) 2021-10-19
IL218599A0 (en) 2012-05-31
PL2480552T3 (pl) 2017-06-30
EA201200525A1 (ru) 2012-09-28
AU2020202600B2 (en) 2021-07-01
BR112012006261A2 (pt) 2020-08-18
AU2018204449B2 (en) 2020-01-23
JP2013505265A (ja) 2013-02-14
SG179194A1 (en) 2012-05-30
JP5795766B2 (ja) 2015-10-14
JP2017075146A (ja) 2017-04-20
AU2020202600A1 (en) 2020-05-14
JP6033362B2 (ja) 2016-11-30
ES2730805T3 (es) 2019-11-12
AP2012006189A0 (en) 2012-04-30
CL2012000707A1 (es) 2012-08-31
ME02656B (me) 2017-06-20
NZ599402A (en) 2014-02-28
SMT201700091B (it) 2017-03-08
SI2480552T1 (sl) 2017-02-28
KR101818779B1 (ko) 2018-01-15
EP3150608B1 (en) 2019-04-10
JP2015187126A (ja) 2015-10-29
UA110466C2 (ru) 2016-01-12
IL248110A0 (en) 2016-11-30
IL218599A (en) 2016-12-29
CN102596958A (zh) 2012-07-18
LT2480552T (lt) 2017-02-10
AU2016262676A1 (en) 2016-12-08
HRP20170197T1 (hr) 2017-04-07
WO2011035231A1 (en) 2011-03-24
BR122021012877B8 (pt) 2021-12-14
AU2010295373A1 (en) 2012-04-26
MX2012003391A (es) 2012-06-27
CA2773772A1 (en) 2011-03-24
AU2010295373B2 (en) 2016-09-29
DK2480552T3 (en) 2017-02-20
PE20160217A1 (es) 2016-05-18
CR20190103A (es) 2019-09-19
ECSP12011817A (es) 2013-02-28
PT2480552T (pt) 2017-02-14
KR20180006499A (ko) 2018-01-17
CA2773772C (en) 2018-06-26
CY1118605T1 (el) 2017-07-12
ES2614651T3 (es) 2017-06-01
CR20120186A (es) 2012-07-04
MX352646B (es) 2017-12-04
PE20210668A1 (es) 2021-04-05
ZA201202175B (en) 2012-11-28
RS55699B1 (sr) 2017-07-31
PE20120995A1 (es) 2012-08-01
AU2018204449A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
AU2020202600B2 (en) 2&#39; -fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2&#39;-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2&#39;-fluoro substituted carba-nucleoside analogs for antiviral treatment
CA2807496C (en) 2&#39;-fluoro substituted carba-nucleoside analogs for antiviral treatment
OA16229A (en) 2&#39;-Fluoro substituted carba-nucleoside analogs for antiviral treatment.
OA16347A (en) 2&#39;-fluoro substituted carba-nucleoside analogs for antiviral treatment.
EA046452B1 (ru) 2&#39;-фторзамещенные карбануклеозидные аналоги для противовирусного лечения